Fig. 1

PHB2 upregulation is associated with poor patient outcomes in GC. A, B Representative images and quantitation of IHC analysis of PHB2 protein expression in 66 pairs of human gastric tumour tissues and corresponding adjacent normal gastric tissues. Scale bar, 50 μm. IRS: Immunoreactive score. Two-tailed Student’s t-test. C, D Western blotting (C) and qRT-PCR (D) analysis of PHB2 expression from 49 gastric tumour (T) patient samples and paired adjacent normal (N) gastric tissues. Data are representatives or mean ± SEM, two-tailed Student’s t-test. E PHB2 was upregulated in GC compared with normal gastric tissues as revealed by analysis of the STAD data in TCGA dataset. Data are mean ± SEM, two-tailed Student’s t-test. F The mRNA expression levels of PHB2 among different stages of GC tissues derived from the TCGA dataset. Data are mean ± SEM, one-way ANOVA followed by Tukey’s multiple comparison. G, H Western blotting (G) and qRT-PCR (H) analysis of PHB2 in a panel of GC cell and normal gastric epithelial cell line GES-1. Data are representatives or mean ± SEM; n = 3 independent experiments, one-way ANOVA followed by Tukey’s multiple comparison. I, J Kaplan–Meier analysis of the probability of overall survival of GC patients derived from the GEO datasets (GSE14210, GSE29272) using the optimal of PHB2 levels as the cut-off